Zenas BioPharma, Inc./$ZBIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Zenas BioPharma, Inc.

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Ticker

$ZBIO
Sector
Health
Primary listing
NASDAQ

Employees

130
Headquarters
Waltham, United States
Website
zenasbio.com

ZBIO Metrics

BasicAdvanced
$970M
-
-$5.31
-
-

Bulls say / Bears say

The company held $274.9 million in cash, cash equivalents, and investments as of June 30, 2025, which management expects will fund operations into the fourth quarter of 2026, providing a substantial runway for its clinical programs. (SEC 10-Q Q2 2025)
Obexelimab is currently being evaluated in multiple Phase 2 and Phase 3 trials across immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus, offering diversified clinical catalysts through 2025 and beyond. (Zenas BioPharma Q1 2025 Press Release)
The company secured non-dilutive financing by out-licensing ZB005 in Greater China to Dianthus and thyroid eye disease programs to Zai Lab, generating upfront fees and potential milestone and royalty streams that de-risk development funding. (GlobeNewswire)
The company’s net loss increased to $85.8 million for the six months ended June 30, 2025, up from $65.8 million a year earlier, indicating widening losses as clinical development accelerates. (SEC 10-Q Q2 2025)
Net cash used in operating activities was $78.8 million in H1 2025, coupled with a $39.3 million decline in cash reserves from $314.2 million as of March 31, 2025 to $274.9 million as of June 30, 2025, underscoring a high burn rate that could pressure future funding needs. (SEC 10-Q Q2 2025)
Amgen’s Uplizna received FDA approval for immunoglobulin G4-related disease in April 2025, establishing first‐to‐market status and creating competitive headwinds that may impair obexelimab’s uptake in its lead indication. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZBIO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs